SVA Plumb Wealth Management LLC lessened its holdings in Bristol-Myers Squibb Company (NYSE:BMY) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 98,551 shares of the biopharmaceutical company’s stock after selling 1,546 shares during the quarter. SVA Plumb Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $5,491,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in BMY. Franklin Resources Inc. lifted its holdings in shares of Bristol-Myers Squibb by 185.2% in the 2nd quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock worth $339,830,000 after buying an additional 3,960,191 shares during the period. Ameriprise Financial Inc. lifted its holdings in shares of Bristol-Myers Squibb by 18.7% in the 1st quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after buying an additional 2,451,390 shares during the period. State Street Corp lifted its holdings in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after buying an additional 1,223,457 shares during the period. Jennison Associates LLC lifted its holdings in shares of Bristol-Myers Squibb by 5.4% in the 2nd quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after buying an additional 1,184,652 shares during the period. Finally, Harbour Capital Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 5,377.1% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,189,789 shares of the biopharmaceutical company’s stock worth $21,353,000 after buying an additional 1,168,066 shares during the period. 69.69% of the stock is currently owned by institutional investors.

In related news, SVP Joseph C. Caldarella sold 9,340 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.23% of the company’s stock.

Several equities research analysts have weighed in on the company. Barclays upped their target price on Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a report on Friday, October 13th. Jefferies Group cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $72.00 price objective for the company. in a research note on Monday, October 16th. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Thursday, October 12th. Leerink Swann upped their price objective on Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. Finally, Citigroup upped their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $64.93.

Bristol-Myers Squibb Company (NYSE BMY) opened at $63.24 on Friday. Bristol-Myers Squibb Company has a 1 year low of $46.01 and a 1 year high of $66.10. The stock has a market capitalization of $103,423.08, a PE ratio of 21.35, a P/E/G ratio of 2.40 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the prior year, the company earned $0.77 earnings per share. The company’s quarterly revenue was up 6.7% on a year-over-year basis. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.thecerbatgem.com/2017/12/02/bristol-myers-squibb-company-bmy-shares-sold-by-sva-plumb-wealth-management-llc.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.